Biomarker: T019-IgE Mimosa/Acacia

Overview

T019-IgE Mimosa/Acacia measures serum immunoglobulin E (IgE) antibodies directed against Mimosa/Acacia pollen allergens. IgE is an immune antibody involved in immediate-type allergic reactions, including allergic rhinitis, conjunctivitis, and asthma. A detectable or elevated result indicates sensitization to the tested pollen extract, but it does not by itself confirm symptomatic allergy or predict reaction severity. The test is clinically useful when interpreted with exposure history, symptoms, and physical examination to help identify pollen allergens associated with respiratory allergy.

Clinical Use Cases

Evaluate suspected seasonal allergic rhinitis or allergic conjunctivitis associated with Mimosa or Acacia pollen exposure.
Assess possible pollen-related asthma or other allergic respiratory symptoms.
Identify sensitization when skin testing is unsuitable because of skin disease, medication use, or risk of adverse reaction.
Support selection of relevant allergens for environmental avoidance counseling or allergen immunotherapy evaluation.
Investigate sensitization and potential IgE cross-reactivity among related or co-exposed pollens in clinical or research settings.

Specimen Types

Serum from venous blood.
Plasma or capillary blood may be accepted by some validated immunoassays, depending on laboratory requirements.

Measurement Methods

Automated serum allergen-specific IgE immunoassay.
Enzyme-linked immunosorbent assay (ELISA).
Radioallergosorbent test (RAST), an older method used in some clinical research.
Immunoblotting or inhibition assays, primarily for research characterization of pollen allergen components and cross-reactivity.

Test Preparation and Influencing Factors

No fasting or other special preparation is generally required for an allergy blood test.
Tell the healthcare professional about all medications and supplements. Do not stop prescribed medicines unless instructed.
Antihistamines generally do not suppress serum-specific IgE measurements, although they can interfere with skin-prick testing.
Omalizumab and some other therapies may affect interpretation of IgE-related testing; medication history should be reviewed clinically.
Results should be interpreted with symptoms, timing and intensity of pollen exposure, seasonality, and examination findings.
A positive result indicates sensitization, not necessarily clinically relevant allergy. The concentration of specific IgE does not reliably predict disease severity, and false-positive results can occur.
Assay calibration, extract composition, pollen species, and laboratory reporting thresholds can affect results. T019 may represent a particular Acacia or Mimosa pollen extract rather than all species in both genera.